Biodimed Conseils is a French consulting company specialized in market access of drugs including Orphan drug, gene and cell therapy, medical devices, acts and diagnosis. The company was founded in 2015 and is based in Paris.
Biodimed Conseils offers to its customer a comprehensive service for health care products (pharmaceuticals and medical devices or technologies) through their life cycle, and performs projects combining its intimate knowledge and understanding of the Health Care Systems and its expertise in medical and economic evaluation.
The team of consultants with a pharmaceutic background and trained in health economic is able to support pharmaceutical companies from the early market access to the price negotiation.
Biodimed has strong knowledge of process and stakeholder within French HTA and public health agencies enabling to deal with complex regulatory or market access issues and to set the most appropriate strategy.

FIECON is a London, UK based health economics consultancy committed to launching products with our pharmaceutical and medical device partners that make a difference in people’s lives. We pursue this objective by generating and communicating the evidence necessary to enable funding agencies and regulators to make fair, efficient decisions about how to allocate scarce healthcare resources to enhance patients’ lives. Since 2018, we have completed over 120 HTA submissions with a 96% success rate of gaining patient access at commercially acceptable prices.
FIECON’s success is a result of our extensive experience synthesizing evidence, designing, building, and quality checking economic models, devising and implementing pricing and market access strategies, and communicating economic value. We have a unique model building platform and partnership approach with our clients which allows us to tackle the dynamic challenges in commercialisation and achieve optimal results in the critical UK marketplace.

Regulatory Pharma Net (RPN), founded in 1999, is a qualified pharmaceutical service and consulting company based in Italy. RPN highly qualified and experienced team can provide complete support for a successful access to the Italian market, from development to registration, local access and life cycle management.
RPN has experience with a wide range of therapeutic areas and particularly with orphan and advanced-therapy medicinal products. RPN support includes early access and P&MA strategic assessments, advisory boards, stakeholder management and full support with national and regional P&R negotiations.

Every patient shall have a fast access to the best possible therapy at a fair price.
For national and international pharmaceutical and medical technology manufacturers, who seek a fast and extensive Market Access at a fair price or strive to maintain an adequate price in their existing market, SmartStep is the consulting company of your choice. SmartStep focuses on the very complex and highly regulated German market and quickly and dynamically develops convincing strategies for all phases and challenges of Market Access. The foundation of SmartStep’s competence is the long-time experience working in the international pharmaceutical industry. Therefore, SmartStep not only performs tasks, but excels at delivering solutions.

SmartStep Nordics specialize in assisting life science industries across the Nordic and European markets. Our expertise lies in crafting effective market access strategies and providing commercially grounded health economic and HTA services, using robust evidence-based tools and real-world data.

Our mission is to facilitate timely access to innovative and cost-effective medical technologies for patients. We bring a wealth of knowledge to the table with the close collaboration of our sister company, SmartStep GmbH in Hamburg and with our partners within the PHAROS Health Care Consulting consortium.

Located in the heart of the Greater Copenhagen Area, the largest life science hub in the EU, we are strategically positioned to serve your needs efficiently.